Knowing that insulin requirements vary widely among persons who have type 1 diabetes, 3-month effectiveness of the Omnipod 5 Automated Insulin Delivery System was evaluated across 6 daily insulin doses.
Patients of a wide range of ages whose total daily insulin needs vary considerably to treat their type 1 diabetes (T1D) can benefit from consistent use of the Omnipod 5 Automated Insulin Delivery (AID) System through improved glycemic control, according to the results of a single-arm outpatient study presented at the recent ADA 82nd Scientific Sessions.
Effectiveness of the AID system was compared with standard therapy for glycemic control for 6 total daily doses (TDD) of insulin: less than 10 U, 10 to less than 20 U, 20 to less than 30 U, 30 to less than 50 U, 50 to less than 65 U, and 65 U and above. This analysis comprised 2 studies: There were 241 adolescents and adults in the main study (age ranges, 6 to younger than 14 years and 14 to 70 years) and 80 children aged 2 to younger than 6 years in the preschool study. Target range for this study was 70 to 180 mg/dL, hypoglycemic range was less than 70 mg/dL, and hyperglycemic range was above 180 mg/dL.
All study participants initiated evaluation with their standard therapy for 14 days before switching to AID for 3 months, after which they were stratified into 1 of the 6 insulin TDD groups.
“AID systems must accommodate a wide range of insulin requirements safely and effectively to apply to a broad population,” the study authors wrote. “A system capable of administering a variety of doses allows adaptability to individuals with differing insulin needs over time.”
Most study participants required 30 to less than 50 U of insulin per day (28%), followed by 10 to less than 20 U (27%), 20 to less than 30 U (18%), 50 to less than 65 U (14%), 65 U or more (9%), and less than 10 U (5%). Patients in the 30-to-less-than-50 U group also were the oldest, with a median (IQR) age of 26 (13-39) years, while those classified in the less-than-10 U group were the youngest, at 3.2 (2.7-4.9) years.
When comparing outcomes between standard therapy and Omnipod 5 AID system use, results for time in range (TIR), time below range (TBR), and time above range (TAR)show across-the-board superiority of AID at improving glycemic outcomes vs standard therapy:
Overall, following 3-month use of AID, TIR improved between 1.7 and 3.2 hours/d, TBR decreased 4 to 9 min/d for participants requiring 20 U or more of daily insulin, and TAR decreased 2.4 to 3 h/day for participants requiring 10 U or more of daily insulin.
Groups using 20 U or less of insulin per day had a slight uptick in TDD, but the study authors attribute this to “the younger age of these cohorts and increasing insulin needs during childhood.”
“Of particular interest, people with a TDD < 10 U saw improved TIR without and increase in time in hypoglycemia,” the authors wrote, “indicating the system’s ability to administer small volumes of insulin for those with low insulin requirements.”
Reference
Schoelwer MJ, Bode BW, Carlson AL, et al. Glycemic outcomes with the Omnipod 5 automated insulin delivery system across total daily insulin doses among people with type 1 diabetes ages 2 to 70 years. Poster presented at: ADA 82nd Scientific Sessions; June 3-7, 2022; https://bit.ly/3afggLT
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More